News & Publications

Kaseb AO, Hasanov E, Cao HST, Xiao L, Vauthey JN, Lee SS, Yavuz BG, Mohamed YI, Qayyum A, Jindal S, Duan F, Basu S, Yadav SS, Nicholas C, Sun JJ, Singh Raghav KP, Rashid A, Carter K, Chun YS, Tzeng CD, Sakamuri D, Xu L, Sun R, Cristini V, Beretta L, Yao JC, Wolff RA, Allison JP, Sharma P. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022 Jan 19. doi: 10.1016/S2468-1253(21)00427-1. Epub 2022 Jan 20. PubMed PMID: 35065057; PubMed Central PMCID: PMC8840977.

Mohamed YI, Duda DG, Awiwi MO, Lee SS, Altameemi L, Xiao L, Morris JS, Wolff RA, Elsayes KM, Hatia RI, Qayyum A, Chamseddine SM, Rashid A, Yao JC, Mahvash A, Hassan MM, Amin HM, Kaseb AO. Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients. Oncotarget. 2022 Dec 6;13:1314-1321. doi: 10.18632/oncotarget.28322. PubMed PMID: 36473155; PubMed Central PMCID: PMC9726202.

Gok Yavuz B, Datar S, Chamseddine S, Mohamed YI, LaPelusa M, Lee SS, Hu ZI, Koay EJ, Tran Cao HS, Jalal PK, Daniel-MacDougall C, Hassan M, Duda DG, Amin HM, Kaseb AO. The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma. Cancers (Basel). 2023 Oct 7;15(19). doi: 10.3390/cancers15194875. Review. PubMed PMID: 37835569; PubMed Central PMCID: PMC10571776.

Chamseddine S, LaPelusa M, Xiao L, Mohamed YI, Lee SS, Hu ZI, Hatia RI, Hassan M, Yao JC, Duda DG, Datar S, Amin HM, Kaseb AO. Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2024;11:455-461. doi: 10.2147/JHC.S452564. eCollection 2024. PubMed PMID: 38463542; PubMed Central PMCID: PMC10921889.

Dogra P, Shinglot V, Ruiz-Ramírez J, Cave J, Butner JD, Schiavone C, Duda DG, Kaseb AO, Chung C, Koay EJ, Cristini V, Ozpolat B, Calin GA, Wang Z. Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer. Mol Cancer. 2024 Aug 2;23(1):156. doi: 10.1186/s12943-024-02060-5. PubMed PMID: 39095771; PubMed Central PMCID: PMC11295620.

Tweardy DJ. Drugging "Undruggable" Disease-Causing Proteins: Focus on Signal Transducer and Activator of Transcription (STAT) 3. Trans Am Clin Climatol Assoc. 2022;132:61-76. PMID: 36196170; PMCID: PMC9480546.

Kwan SY, Jiao J, Joon A, Wei P, Petty LE, Below JE, Daniel CR, Wu X, Zhang J, Jenq RR, Futreal PA, Hawk ET, McCormick JB, Fisher-Hoch SP, Beretta L. Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease. Hepatology. 2021 Oct 11;. doi: 10.1002/hep.32197. [Epub ahead of print] PubMed PMID: 34633706; PMCID: PMC8930512.

Jiao J, Kwan SY, Sabotta CM, Tanaka H, Veillon L, Warmoes MO, Lorenzi PL, Wang Y, Wei P, Hawk ET, Almeda JL, McCormick JB, Fisher-Hoch SP, Beretta L. Circulating Fatty Acids Associated with Advanced Liver Fibrosis and Hepatocellular Carcinoma in South Texas Hispanics. Cancer Epidemiol Biomarkers Prev. 2021 Sep;30(9):1643-1651. doi: 10.1158/1055-9965.EPI-21-0183. Epub 2021 Jun 21. PubMed PMID: 34155064; PubMed Central PMCID: PMC8419070.

Heredia NI, Zhang X, Balakrishnan M, Daniel CR, Hwang JP, McNeill LH, Thrift AP. Physical activity and diet quality in relation to non-alcoholic fatty liver disease: A cross-sectional study in a representative sample of U.S. adults using NHANES 2017-2018. Prev Med. 2022 Jan;154:106903. doi: 10.1016/j.ypmed.2021.106903. Epub 2021 Dec 1. PubMed PMID: 34861339; PubMed Central PMCID: PMC8724407.

Kwan SY, Sabotta CM, Joon A, Wei P, Petty LE, Below JE, Wu X, Zhang J, Jenq RR, Hawk ET, McCormick JB, Fisher-Hoch SP, Beretta L. Gut microbiome alterations associated with Diabetes in Mexican Americans in South Texas. mSystems. 2022 Apr 28:e0003322. doi: 10.1128/msystems.00033-22. Epub ahead of print. PMID: 35477306.

Sabotta CM, Kwan SY, Petty LE, Below JE, Joon A, Wei P, Fisher-Hoch SP, McCormick JB, Beretta L. Genetic variants associated with circulating liver injury markers in Mexican Americans, a population at risk for non-alcoholic fatty liver disease. Front Genet. 2022;13:995488. doi: 10.3389/fgene.2022.995488. eCollection 2022. PubMed PMID: 36386790; PubMed Central PMCID: PMC9644071.

Zhang X, Daniel CR, Soltero V, Vargas X, Jain S, Kanwal F, Thrift AP, Balakrishnan M. A Study of Dietary Patterns Derived by Cluster Analysis and Their Association With Metabolic Dysfunction-Associated Steatotic Liver Disease Severity Among Hispanic Patients. Am J Gastroenterol. 2024 Mar 1;119(3):505-511. doi: 10.14309/ajg.0000000000002508. Epub 2023 Sep 20. PMID: 37737674; PMCID: PMC11001785.

Kwan S-Y, Sabotta CM, Cruz L, Wong M, Ajami N, McCormick J, Fisher-Hoch S, Beretta L. Gut phageome in Mexican Americans: a population at high risk for metabolic dysfunction-associated steatotic liver disease and diabetes. mSystems. 2024 Sep 17;9(9):e0043424. doi: 10.1128/msystems.00434-24. Epub 2024 Aug 21. PubMed PMID: 39166873; PubMed Central PMCID: PMC11406975.

Kwan S-Y, Gonzales KA, Jamal MA, Stevenson HL, Tan L, Lorenzi PL, Futreal PA, Hawk ET, McCormick JB, Fisher-Hoch SP, Jenq RR, Beretta L. Protection against fibrosis by a bacterial consortium in metabolic dysfunction-associated steatohepatitis and the role of amino acid metabolism. Gut Microbes. 2024 Jan-Dec;16(1):2399260. doi: 10.1080/19490976.2024.2399260. Epub 2024 Sep 6. PubMed PMID: 39239875; PubMed Central PMCID: PMC11382720.

Moussa I, Day RS, Li R, Kaseb A, Jalal PK, Daniel-MacDougall C, Hatia RI, Abdelhakeem A, Rashid A, Chun YS, Li D, Hassan MM. Association of dietary fat intake and hepatocellular carcinoma among US adults. Cancer Med. 2021 Oct;10(20):7308-7319. doi: 10.1002/cam4.4256. Epub 2021 Sep 18. PubMed PMID: 34535983; PubMed Central PMCID: PMC8525131.

Zheng J, Daniel CR, Hatia RI, Stuff J, Abdelhakeem AA, Rashid A, Chun YS, Jalal PK, Kaseb AO, Li D, Hassan MM. Dietary N-Nitroso Compounds and Risk of Hepatocellular Carcinoma: A USA-Based Study. Hepatology. 2021 Dec;74(6):3161-3173. doi: 10.1002/hep.32046. Epub 2021 Aug 26. PubMed PMID:34233041; PubMed Central PMCID: PMC8639645.

Moussa I, Day RS, Li R, Du XL, Kaseb AO, Jalal PK, Daniel-MacDougall C, Hatia RI, Abdelhakeem A, Rashid A, Chun YS, Li D, Hassan MM. Dietary Patterns and Hepatocellular Carcinoma Risk among US Adults. Nutrients. 2021 Jun 11;13(6). doi: 10.3390/nu13062011. PubMed PMID: 34208122; PubMed Central PMCID: PMC8230753.

Wang Z, Wei P. IMIX: a multivariate mixture model approach to association analysis through multiomics data integration. Bioinformatics. 2021 Apr 1;36(22-23):5439-5447. doi: 10.1093/bioinformatics/btaa1001. PubMed PMID: 33258948; PubMed Central PMCID: PMC8016490.

Wei P. Radiomics, deep learning and early diagnosis in oncology. Emerg Top Life Sci. 2021 Dec 21;5(6):829-835. doi: 10.1042/ETLS20210218. Review. PubMed PMID: 34874454; PubMed Central PMCID: PMC8786297.

Wang Z, Lu Y, Fornage M, Jiao L, Shen J, Li D, Wei P. Identification of novel susceptibility methylation loci for pancreatic cancer in a two-phase epigenome-wide association study. Epigenetics. 2022 Nov;17(11):1357-1372. doi: 10.1080/15592294.2022.2026591. Epub 2022 Jan 14. PubMed PMID: 35030986; PubMed Central PMCID: PMC9586592.

Singh S, Clemente LC, Parra ER, Tchakarov A, Yang C, Li Y, Long JP, Yee C, Lin JS. Urinary T cells are detected in patients with immune checkpoint inhibitor-associated immune nephritis that are clonotypically identical to kidney T cell infiltrates. Oncoimmunology. 2022;11(1):2124678. doi: 10.1080/2162402X.2022.2124678. eCollection 2022. PubMed PMID: 36185804; PubMed Central PMCID: PMC9519023.

Su X, Li Y, Müller P, Hsu CW, Pan H, Do KA. A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling. Pharm Stat. 2022 Nov;21(6):1149-1166. doi: 10.1002/pst.2249. Epub 2022 Jun 24. PubMed PMID: 35748220; PubMed Central PMCID: PMC10134386.

Chi S, Flowers CR, Li Z, Huang X, Wei P. MASH: Mediation Analysis of Survival Outcome and High-dimensional Omics Mediators with Application to Complex Diseases. Ann Appl Stat. 2024 Jun;18(2):1360-1377. doi: 10.1214/23-aoas1838. Epub 2024 Apr 5. PubMed PMID: 39328363; PubMed Central PMCID: PMC11426188.

Saldarriaga OA, Dye B, Pham J, Wanninger TG, Millian D, Kueht M, Freiberg B, Utay N, Stevenson HL. Comparison of liver biopsies before and after direct-acting antiviral therapy for hepatitis C and correlation with clinical outcome. Sci Rep. 2021 Jul 15;11(1):14506. doi: 10.1038/s41598-021-93881-7. PubMed PMID: 34267267; PubMed Central PMCID: PMC8282660.

Millian DE, Saldarriaga OA, Wanninger T, Burks JK, Rafati YN, Gosnell J, Stevenson HL. Cutting-Edge Platforms for Analysis of Immune Cells in the Hepatic Microenvironment-Focus on Tumor-Associated Macrophages in Hepatocellular Carcinoma. Cancers (Basel). 2022 Apr 7;14(8). doi: 10.3390/cancers14081861. Review. PubMed PMID: 35454766; PubMed Central PMCID: PMC9026790.

Kwan SY, Slayden AN, Coronado AR, Marquez RC, Chen H, Wei P, Savage MI, Vornik LA, Fox JT, Sei S, Liang D, Stevenson HL, Wilkerson GK, Gagea M, Brown PH, Beretta L. Treatment Strategies and Mechanisms Associated with the Prevention of NASH-Associated HCC by a Toll-like Receptor 4 Inhibitor. Cancer Prev Res (Phila). 2023 Jan 4;16(1):17-28. doi: 10.1158/1940-6207.CAPR-22-0332. PubMed PMID: 36162136; PubMed Central PMCID: PMC9812917.

Wilhelm AB, Cunningham AG, Kassab C, Fitz EC, Dong J, Radhakrishnan RS, Ranganathan S, Tan D, Stevenson HL. Pediatric combined hepatocellular-cholangiocarcinoma (cHCC-CC) with neuroendocrine features: distinguishing genetic alterations detected by chromosomal microarray. Diagn Pathol. 2023 Feb 13;18(1):20. doi: 10.1186/s13000-023-01305-z. PubMed PMID: 36782322; PubMed Central PMCID: PMC9926826.

Zhang Y, Zhao Z, Huang LA, Liu Y, Yao J, Sun C, Li Y, Zhang Z, Ye Y, Yuan F, Nguyen TK, Garlapati NR, Wu A, Egranov SD, Caudle AS, Sahin AA, Lim B, Beretta L, Calin GA, Yu D, Hung MC, Curran MA, Rezvani K, Gan B, Tan Z, Han L, Lin C, Yang L. Molecular mechanisms of snoRNA-IL-15 crosstalk in adipocyte lipolysis and NK cell rejuvenation. 2023 Aug 8;35(8):1457-1473.e13. doi: 10.1016/j.cmet.2023.05.009. Epub 2023 Jun 16. PubMed PMID: 37329887; PubMed Central PMCID: PMC10712687.

Gu L, Zhu Y, Lee M, Nguyen A, Ryujin NT, Huang JY, Pandit SK, Chamseddine S, Xiao L, Mohamed YI, Kaseb AO, Karin M, Shalapour S. Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells. Proc Natl Acad Sci U S A. 2023 May 9;120(19):e2300706120. doi: 10.1073/pnas.2300706120. Epub 2023 May 1. PubMed PMID: 37126700; PubMed Central PMCID: PMC10175751.

Dibra D, Gagea M, Qi Y, Chau GP, Su X, Lozano G. p53R245W Mutation Fuels Cancer Initiation and Metastases in NASH-driven Liver Tumorigenesis. Cancer Res Commun. 2023 Dec 2;. doi: 10.1158/2767-9764.CRC-23-0218. [Epub ahead of print] PubMed PMID: 38047594; PubMed Central PMCID: PMC10761659.

Tran Cao HS, Witt RG, Elsayes KM, Baiomy AA, Xiao L, Palmquist S, Lee SS, Mohamed YI, Mahvash A, Tzeng CD, Chun YS, Koay EJ, Rashid A, Hassan MM, Yao JC, Vauthey JN, Kaseb AO. Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging Features. Oncologist. 2024 Jun 3;29(6):e803-e810. doi: 10.1093/oncolo/oyad329. PMID: 38159256; PMCID: PMC11144988.

Yim SY, Lee JS. An Overview of the Genomic Characterization of Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021;8:1077-1088. doi: 10.2147/JHC.S270533. eCollection 2021. Review. PubMed PMID: 34522690; PubMed Central PMCID: PMC8434863.

Lee SH, Jeong YS, Lee S, Sohn BH, Hwang HK, Choi GH, Kang CM, Choi JS, Lee WJ, Cheong JH, Jang HJ, Kaseb A, Roberts L, Yim SY, Chun YS, Lee JS. Two distinct stem cell-like subtypes of hepatocellular carcinoma with clinical significance and their therapeutic potentials. Cancer Commun (Lond). 2022 Jan 15. doi: 10.1002/cac2.12251. Epub 2022 Jan 15. PMID: 35032367; PMCID: PMC8822477.

Qayyum A, Bhosale P, Aslam R, Avritscher R, Ma J, Pagel MD, Sun J, Mohamed Y, Rashid A, Beretta L, Kaseb AO. Effect of sarcopenia on systemic targeted therapy response in patients with advanced hepatocellular carcinoma. Abdom Radiol (NY). 2021 Mar;46(3):1008-1015. doi: 10.1007/s00261-020-02751-9. Epub 2020 Sep 24. PubMed PMID: 32974761; PubMed Central PMCID: PMC8191337.

Cazoulat G, Anderson BM, McCulloch MM, Rigaud B, Koay EJ, Brock KK. Detection of vessel bifurcations in CT scans for automatic objective assessment of deformable image registration accuracy. Med Phys. 2021 Oct;48(10):5935-5946. doi: 10.1002/mp.15163. Epub 2021 Aug 25. PubMed PMID: 34390007; PubMed Central PMCID: PMC9132059.

De B, Tran Cao HS, Vauthey JN, Manzar GS, Corrigan KL, Raghav KPS, Lee SS, Tzeng CD, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Javle M, Ludmir EB, Koay EJ. Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States. Cancer. 2022 Jul 1;128(13):2529-2539. doi: 10.1002/cncr.34223. Epub 2022 Apr 13. PubMed PMID: 35417569; PubMed Central PMCID: PMC9177808.

Fujita M, Chen MM, Siwak DR, Sasagawa S, Oosawa-Tatsuguchi A, Arihiro K, Ono A, Miura R, Maejima K, Aikata H, Ueno M, Hayami S, Yamaue H, Chayama K, Lee JS, Lu Y, Mills GB, Liang H, Nishizuka SS, Nakagawa H. Proteo-genomic characterization of virus-associated liver cancers reveals potential subtypes and therapeutic targets. Nat Commun. 2022 Oct 29;13(1):6481. doi: 10.1038/s41467-022-34249-x. PubMed PMID: 36309506; PubMed Central PMCID: PMC9617926.

Lee SH, Yim SY, Jeong YS, Li QX, Kang SH, Sohn BH, Kumar SV, Shin JH, Choi YR, Shim JJ, Kim H, Kim JH, Kim S, Guo S, Johnson RL, Kaseb A, Kang KJ, Chun YS, Jang HJ, Lee BG, Woo HG, Ha MJ, Akbani R, Roberts LR, Wheeler DA, Lee JS. Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes. Hepatology. 2022 Dec;76(6):1634-1648. doi: 10.1002/hep.32490. Epub 2022 Jun 29. PubMed PMID: 35349735; PubMed Central PMCID: PMC9519807.

Jung J, Park S, Jang Y, Lee SH, Jeong YS, Yim SY, Lee JS. Clinical Significance of Glycolytic Metabolic Activity in Hepatocellular Carcinoma. Cancers (Basel). 2022 Dec 28;15(1). doi: 10.3390/cancers15010186. PubMed PMID: 36612182; PubMed Central PMCID: PMC9818850.

Wang CX, Elganainy D, Zaid MM, Butner JD, Agrawal A, Nizzero S, Minsky BD, Holliday EB, Taniguchi CM, Smith GL, Koong AC, Herman JM, Das P, Maitra A, Wang H, Wolff RA, Katz MHG, Crane CH, Cristini V, Koay EJ. Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2022 Sep 1;114(1):163-172. doi: 10.1016/j.ijrobp.2022.04.044. Epub 2022 May 26. PubMed PMID: 35643254; PubMed Central PMCID: PMC10042520.

Engel BJ, Paolillo V, Uddin MN, Gonzales KA, McGinnis KM, Sutton MN, Patnana M, Grindel BJ, Gores GJ, Piwnica-Worms D, Beretta L, Pisaneschi F, Gammon ST, Millward SW. Gender Differences in a Mouse Model of Hepatocellular Carcinoma Revealed Using Multi-Modal Imaging. Cancers (Basel). 2023 Jul 26;15(15). doi: 10.3390/cancers15153787. PubMed PMID: 37568603; PubMed Central PMCID: PMC10417617.

Kim J, Zimmerman MA, Shin WY, Boettcher BT, Lee JS, Park JI, Ali M, Yang M, Mishra J, Hagen CE, McGraw JE, Mathison A, Woehlck HJ, Lomberk G, Camara AKS, Urrutia RA, Stowe DF, Hong JC. Effects of Subnormothermic Regulated Hepatic Reperfusion on Mitochondrial and Transcriptomic Profiles in a Porcine Model. Ann Surg. 2023 Feb 1;277(2):e366-e375. doi: 10.1097/SLA.0000000000005156. Epub 2023 Jan 10. PubMed PMID: 34387201; PubMed Central PMCID: PMC8840998.

Wright T, Wang Y, Stratton SA, Sebastian M, Liu B, Johnson DG, Bedford MT. Loss of the methylarginine reader function of SND1 confers resistance to hepatocellular carcinoma. Biochem J. 2023 Nov 29;480(22):1805-1816. doi: 10.1042/BCJ20230384. PubMed PMID: 37905668; PubMed Central PMCID: PMC10860161.

Cazoulat G, Gupta AC, Al Taie MM, Koay EJ, Brock KK. Analysis and prediction of liver volume change maps derived from computational tomography scans acquired pre- and post-radiation therapy. Phys Med Biol. 2023 Oct 4;68(20):205009. doi: 10.1088/1361-6560/acfa5f. PMID: 37714187; PMCID: PMC10547850.